Oral pill trial to halt HIV in women is stopped

Apr 19, 2011

A trial of an oral pill aimed at preventing HIV infection in African women has been halted due to poor results, the trial operator Family Health International announced this week.

The US Centers for Disease Control described the results as "disappointing," and in a Monday statement said the trial's monitoring committee had decided it "could not demonstrate efficacy even if it continued to its originally planned conclusion."

The same oral treatment, known as pre-exposure prophylaxis (PrEP) for HIV prevention, has been shown to reduce risk of HIV transmission among men who have sex with men by between 73 and 90 percent.

The trial included 2,000 African women in Kenya, South Africa and Tanzania. Trial subjects were taking oral tenofovir and emtricitabine, marketed as Truvada by the California-based Gilead Sciences Inc., or a placebo.

Researchers said that the rate of new HIV infections in both the drug and placebo groups was the same, with 56 new HIV cases equally distributed across both sections of the study.

They also noted that the overall pregnancy rate among women in the study was nine percent, with the highest rates seen in women taking birth control pills. More study is needed to determine if the anti-HIV treatment had a disabling effect on the oral contraceptives.

"While this development was not what we would have hoped for, Gilead believes that antiretroviral therapies remain a promising potential HIV prevention strategy," Gilead Sciences said in a statement.

"We continue to support ongoing studies evaluating the company's antiretroviral therapies as potential preventatives."

The CDC sent out an email announcement about the FHI trial's end on Monday.

"Given today's results, CDC cautions against women using PrEP for HIV prevention at this time," it said.

"We will not know if PrEP is effective for women, couples, or injection drug users until the conclusive results of this and other trials are reported."

Explore further: Small changes in eGFR with TDF preexposure prophylaxis

add to favorites email to friend print save as pdf

Related Stories

AIDS prevention pill study halted; no benefit seen

Apr 18, 2011

Researchers are stopping a study that tests a daily pill to prevent infection with the AIDS virus in thousands of African women because partial results show no signs that the drug is doing any good.

Daily dose of HIV drug reduces risk of HIV infection

Nov 23, 2010

A daily dose of an oral antiretroviral drug, currently approved to treat HIV infection, reduced the risk of acquiring HIV infection by 43.8 percent among men who have sex with men. The findings, a major advance in HIV prevention ...

Recommended for you

Small changes in eGFR with TDF preexposure prophylaxis

Dec 23, 2014

(HealthDay)—For HIV-1-uninfected members of serodiscordant couples, tenofovir disoproxil fumarate (TDF) used as preexposure prophylaxis (PrEP) is associated with a small decrease in estimated glomerular ...

FDA to ease ban on blood donations by gay men

Dec 23, 2014

Federal officials have moved closer to overturning a decades-old ban on blood donations from gay and bisexual men, but activists say the proposed alternative would continue to stigmatize men who have sex ...

Consumer group sues Aetna, alleges discrimination

Dec 23, 2014

A consumer advocacy group has filed a class-action lawsuit against Aetna Inc. saying a new policy violates the privacy of people with HIV and AIDS by requiring them to get their medications from its mail-order pharmacy.

Cambodia orders probe into mass HIV infection

Dec 18, 2014

Cambodian Prime Minister Hun Sen on Thursday ordered a probe into an apparent mass HIV infection believed to have been spread by contaminated needles, as the number of suspected cases passed 100.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.